Diffuse midline glioma, H3 K27M-mutant

This early-phase trial is testing a new type of cell therapy called GD2 CAR-T cells in children and young adults with diffuse midline glioma, a rare and aggressive brain tumor. The treatment involves collecting the patient's own immune cells, modifying them to recognize and attac…

This trial tests a drug called selinexor combined with standard radiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) that has a specific genetic change (H3 K27M mutation). The study has two parts: first, fi…

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This phase 3 trial tests whether the drug ONC201 works better than everolimus for children and adults with DIPG, a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The goal is to see which drug …

This early-phase trial is testing whether adding the drug atovaquone to standard radiation therapy is safe and tolerable for children with certain malignant brain tumors, including high-grade glioma, diffuse midline glioma, and medulloblastoma. The study includes two groups: chil…

This phase 2 trial is testing whether combining the drug ONC201 with other treatments (like paxalisib or a cancer-killing virus called DNX-2401) can help children and young adults with diffuse midline gliomas, a rare and aggressive brain cancer. The study enrolls 360 participants…

This pilot study tests whether adding APG-157 (a pastille dissolved in the mouth) to standard bevacizumab can help people with recurrent high-grade glioma. About 30 participants will take APG-157 three times daily while continuing bevacizumab. The study tracks survival, tumor res…

This study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…

This study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…

This Phase 3 trial tests the drug ONC201 (dordaviprone) in people newly diagnosed with a rare brain cancer called H3 K27M-mutant diffuse glioma. Participants receive either ONC201 or a placebo after completing standard radiotherapy. The study aims to see if the drug helps them li…

This early-phase trial is testing a new vaccine (rHSC-DIPGVax) made from pieces of tumor proteins, given together with two immunotherapy drugs (balstilimab and zalifrelimab), in children with DIPG or diffuse midline glioma. The goal is to see if the combination is safe and tolera…

This early-phase trial is testing the drug larotrectinib in 15 children (up to age 21) with newly diagnosed high-grade glioma or DIPG that have a specific genetic change called NTRK fusion. The study aims to see if the drug can control the disease after two cycles, and how safe i…

This early study tests whether focused ultrasound can safely open the blood-brain barrier in children with progressive diffuse midline glioma (DMG), a rare and aggressive brain tumor. Ten children aged 4–21 will receive oral etoposide chemotherapy after ultrasound treatment to al…

This early-stage trial tests whether a new immune cell therapy called GD2 CAR T cells can be safely made and given to children and adults with a rare, aggressive brain tumor called H3K27M-mutant diffuse midline glioma. The study aims to find the right dose and check for side effe…

This early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.

This study tests whether giving two drugs (cetuximab and bevacizumab) directly into the brain's blood vessels each month is safe and can shrink tumors or slow their growth. It includes children and young adults under 22 with certain types of brain tumors that have come back or no…

This study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…

This study is testing whether an artificial intelligence (AI) model can accurately predict the molecular subtype of midline gliomas (a type of brain tumor) using MRI scans taken before surgery. Researchers will compare the AI's predictions with standard lab tests after surgery to…

This study is collecting data from 1,650 people with various brain tumors to see if the updated 2021 WHO classification system helps doctors group patients more accurately and choose better treatments. Researchers will track responses to therapy, survival, and tumor features over…

This study creates a central registry and tissue bank for people with DIPG or DMG, rare and aggressive brain tumors. Researchers will collect medical information, scans, and tumor samples from up to 1,500 patients of any age. The goal is to understand the biology of these tumors …